Our findings contribute to a new understanding of mechanisms underlying the overall negative clinical outcome associated with ERRα in prostate cancer and provide a rationale for the investigation of ERRα as a therapeutic target to treat primary prostate cancers and their associated bone metastases. The gene discussed is ESRRA; the disease is prostate carcinoma.